[BostonCard]

My guess is the GOP's preferred strategy will be to let private companies chart their own path with businesses conducting their own business risk assessment.   The profit potential and PR benefits are clear enough for most companies without the government trying to pick winners.

https://www.medicalcountermeasures.gov/a...VID19.aspx

$456,237,081.00 to Janssen (J&J) to "Support development to licensure of a vaccine to combat COVID-19 using Janssen’s established Adenovirus 26 platform."
$430,298,520.00 to Moderna for "mRNA based SARS-CoV-2 vaccine encoding a pre-fusion stabilized Spike protein"
$30,775,336.46 to Sanofi for "Recombinant SARS-CoV-2 spike protein with transmembrane region deleted produced using Sanofi’sFDA-licensed seasonal influenza vaccine Flublok® facilities"

That's just BARDA's funding of vaccine development.  They are also funding diagnostics, therapeutics (disclosure, I work for one of the company's whose product is being funded).

BC

---

Some more news on vaccine development:

https://www.wsj.com/articles/pfizer-coro...1588094064

(might be behind a paywall)

Pfizer said Tuesday it will begin testing of its experimental vaccine in the U.S. as early as next week. On Monday, Oxford University researchers said their vaccine candidate could be available for emergency use as early as September if it passes muster in studies, while biotech Moderna Inc. said it was preparing to enter its vaccine into the second phase of human testing.

Specifically about Pfizer's effort:

New York-based Pfizer is working on vaccine candidates with Germany’s BioNTech SE. The shots are based on an emerging gene-based technology known as messenger RNA, or mRNA, which carry instructions from DNA to the body’s cells to make certain proteins.
Testing of a vaccine, which has already started in Germany, could start in the U.S. as early as next week if health regulators sign off, Pfizer’s Mr. Bourla said. Results from the study could come as early as next month, he said.
If further testing also proves successful, Pfizer could start distributing the vaccine on an emergency basis in the fall and receive approval for widespread distribution by year’s end, Mr. Bourla said.

BC

[BostonCard]

My guess is the GOP's preferred strategy will be to let private companies chart their own path with businesses conducting their own business risk assessment.   The profit potential and PR benefits are clear enough for most companies without the government trying to pick winners.

https://www.medicalcountermeasures.gov/a...VID19.aspx

$456,237,081.00 to Janssen (J&J) to "Support development to licensure of a vaccine to combat COVID-19 using Janssen’s established Adenovirus 26 platform."
$430,298,520.00 to Moderna for "mRNA based SARS-CoV-2 vaccine encoding a pre-fusion stabilized Spike protein"
$30,775,336.46 to Sanofi for "Recombinant SARS-CoV-2 spike protein with transmembrane region deleted produced using Sanofi’sFDA-licensed seasonal influenza vaccine Flublok® facilities"

That's just BARDA's funding of vaccine development.  They are also funding diagnostics, therapeutics (disclosure, I work for one of the company's whose product is being funded).

BC

---

Some more news on vaccine development:

https://www.wsj.com/articles/pfizer-coro...1588094064

(might be behind a paywall)

Pfizer said Tuesday it will begin testing of its experimental vaccine in the U.S. as early as next week. On Monday, Oxford University researchers said their vaccine candidate could be available for emergency use as early as September if it passes muster in studies, while biotech Moderna Inc. said it was preparing to enter its vaccine into the second phase of human testing.

Specifically about Pfizer's effort:

New York-based Pfizer is working on vaccine candidates with Germany’s BioNTech SE. The shots are based on an emerging gene-based technology known as messenger RNA, or mRNA, which carry instructions from DNA to the body’s cells to make certain proteins.
Testing of a vaccine, which has already started in Germany, could start in the U.S. as early as next week if health regulators sign off, Pfizer’s Mr. Bourla said. Results from the study could come as early as next month, he said.
If further testing also proves successful, Pfizer could start distributing the vaccine on an emergency basis in the fall and receive approval for widespread distribution by year’s end, Mr. Bourla said.

BC